Comparing the current results to its competitors, Neuroone Medical Technologies reported Revenue increase in the 2 quarter 2026 by 72.46 % year on year. The sales growth was above Neuroone Medical Technologies's competitors' average revenue growth of 9.62 %, achieved in the same quarter.
Neuroone Medical Technologies Corp, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 45.37 %
Neuroone Medical Technologies's Comment on Competition and Industry Peers
NeuroOne Medical Technologies Corporation operates in multiple neurological therapy markets. In epilepsy diagnosis, its Evo Cortical and Evo sEEG products compete with seizure diagnostic products from Ad-Tech Medical Instrument Corporation, PMT Corporation, Dixi Medical, and other companies developing thin film technologies. In neuro-ablation, its OneRF Brain Ablation System competes with Medtronic, Monteris Medical, and Clearpoint's LITT technology. For trigeminal neuralgia treatment, competitors include Boston Scientific, Avanos RF ablation systems, and companies utilizing balloon compression methods. In the basivertebral nerve ablation (BVNA) market, competitors are Boston Scientific and Stryker's BVNA systems. In spinal cord stimulation, competitors include Medtronic, Boston Scientific, Abbott, Globus, and Biotronik.
Due to outstanding performance in Overall company, revenue grew by 72.46 % Neuroone Medical Technologies Corp improved its market share, to approximately 0.01 %.
Publicly Traded Peers of Neuroone Medical Technologies Corp
Electrocore Inc Share Performance
-8.12%
Over The Past 5 Days
Electrocore Inc
Profile
Electrocore Inc operates on a business model that focuses on developing and commercializing innovative neuromodulation therapies. They utilize non-invasive vagus nerve stimulation (nVNS) to offer patients drug-free solutions for various medical conditions. The company's approach involves leveraging their understanding of the human body's electrochemical signaling system to provide targeted and effective treatments across multiple therapeutic areas.
Neuropace Inc's business model revolves around the development and commercialization of medical devices for the treatment of neurological disorders, primarily focusing on epilepsy.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Neuroone Medical Technologies Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neuroone Medical Technologies Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
